NIKKEI 225
38,236.07 -37.98 (-0.10%) HANG SENG
18,543.86 +336.73 (+1.85%) CRUDE OIL
79.18 +0.23 (+0.29%) GOLD FUTURES
2,312.20 +2.60 (+0.11%) DOW
38,225.66 +322.37 (+0.85%) Bitcoin GBP
47,256.89 +1,816.01 (+4.00%)
Medigene AG (MDG1.BE)
| Previous close | 1.4100 |
| Open | 1.4100 |
| Bid | 1.5700 x 0 |
| Ask | 1.6100 x 0 |
| Day's range | 1.4100 - 1.4100 |
| 52-week range | 1.3750 - 2.6500 |
| Volume | |
| Avg. volume | 101 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 26 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Globe NewswireMedigene AG Expands Patent Portfolio with European Patent Grant for its NY-ESO-1 – targeted T Cell Receptor
Planegg/Martinsried, May 2, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, announces today that the Company has been issued a patent by the European Patent Office protecting its T cell receptor (TCR) targeting NY-ESO-1 (New York esophageal squamous cell carcinoma 1), a well-recognized and validated cancer-testis antigen, which is expressed in multip
- Globe Newswire
Medigene Presents Superior TCR-T Cell Functionality by Inclusion of a Costimulatory Switch Protein
Planegg/Martinsried, May 2, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, presented superior T cell receptor engineered T (TCR-T) cell functionality upon combination of optimal affinity 3S (sensitive, specific and safe) TCRs with the PD1-41BB costimulatory switch protein (CSP) at the 7th International Neoantigen Summit held in Amsterdam, Netherland
GlobeNewswireMedigene AG reports Financial Results and Business Update for Q1 2024
Planegg/Martinsried, April 26, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today reported financial results for the first quarter of 2024. The full Quarterly Statement Q1 2024 can be downloaded here: https://medigene.com/investors-media/reports-presentations/. "During the first quarter of 2024, our focus remained on executing our strategic plan a
